Literature DB >> 27777937

Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases.

Terek Wehbe1, Majid Abi Saab2, Nassim Abi Chahine3, Talar Margossian4.   

Abstract

We treated 2 patients with progressive, refractory scleroderma with a combined immunotherapy approach using plasmapheresis followed by rituximab and then intravenous umbilical-cord-derived allogeneic mesenchymal stem cells (MSCs). Both patients improved subjectively and objectively for over a year. Upon recurrence of their symptoms, the patients were treated again with allogeneic MSCs alone with a very good response. The combination was well tolerated and effective suggesting a large scale study may be warranted in progressive, refractory Scleroderma.

Entities:  

Keywords:  Mesenchymal stem cells (MSCs); plasmapheresis; refractory scleroderma

Year:  2016        PMID： 27777937      PMCID： PMC5067369          DOI： 10.21037/sci.2016.09.03

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN： 2306-9759


  17 in total

1.  Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.

Authors:  K Le Blanc; L Tammik; B Sundberg; S E Haynesworth; O Ringdén
Journal:  Scand J Immunol       Date:  2003-01       Impact factor: 3.487

2.  Mesenchymal stem cells derived from Wharton's jelly: comparative phenotype analysis between tissue and in vitro expansion.

Authors:  Talar Margossian; Loic Reppel; Nehman Makdissy; Jean-François Stoltz; Danièle Bensoussan; Céline Huselstein
Journal:  Biomed Mater Eng       Date:  2012       Impact factor: 1.300

3.  Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.

Authors:  Lynne M Ball; Maria E Bernardo; Helene Roelofs; Maarten J D van Tol; Benedetta Contoli; Jaap Jan Zwaginga; Maria Antonia Avanzini; Antonella Conforti; Alice Bertaina; Giovanna Giorgiani; Cornelia M Jol-van der Zijde; Marco Zecca; Katarina Le Blanc; Francesco Frassoni; Rudolph Maarten Egeler; Willem E Fibbe; Arjan C Lankester; Franco Locatelli
Journal:  Br J Haematol       Date:  2013-08-31       Impact factor: 6.998

4.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

5.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

6.  T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression.

Authors:  Elena Klyushnenkova; Joseph D Mosca; Valentina Zernetkina; Manas K Majumdar; Kirstin J Beggs; Donald W Simonetti; Robert J Deans; Kevin R McIntosh
Journal:  J Biomed Sci       Date:  2005       Impact factor: 8.410

Review 7.  Classification of systemic sclerosis. Visions and reality.

Authors:  F A Wollheim
Journal:  Rheumatology (Oxford)       Date:  2005-05-03       Impact factor: 7.580

8.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.

Authors:  Katarina Le Blanc; Charlotte Tammik; Kerstin Rosendahl; Eva Zetterberg; Olle Ringdén
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

9.  A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype.

Authors:  Ruth S Waterman; Suzanne L Tomchuck; Sarah L Henkle; Aline M Betancourt
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

Review 10.  Classification criteria in rheumatic diseases: a review of methodologic properties.

Authors:  Sindhu R Johnson; Oemer-Necmi Goek; Davinder Singh-Grewal; Steven C Vlad; Brian M Feldman; David T Felson; Gillian A Hawker; Jasvinder A Singh; Daniel H Solomon
Journal:  Arthritis Rheum       Date:  2007-10-15
View more
  3 in total

Review 1.  Human Mesenchymal Stem/Stromal Cells in Immune Regulation and Therapy.

Authors:  Éva Mezey
Journal:  Stem Cells Transl Med       Date:  2022-03-17       Impact factor: 6.940

Review 2.  Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives.

Authors:  Mina Abedi; Sepideh Alavi-Moghadam; Moloud Payab; Parisa Goodarzi; Fereshteh Mohamadi-Jahani; Forough Azam Sayahpour; Bagher Larijani; Babak Arjmand
Journal:  Cell Regen       Date:  2020-12-01

Review 3.  Clinical application of mesenchymal stem cells in rheumatic diseases.

Authors:  Yajing Wang; Dan Ma; Zewen Wu; Baoqi Yang; Rong Li; Xingxing Zhao; Helin Yang; Liyun Zhang
Journal:  Stem Cell Res Ther       Date:  2021-11-09       Impact factor: 6.832
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.